Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
PBIOPALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)
August 7, 2025Clinical Trials
Read more →